|
Diagnosis & Comorbidities in Cushing’s Disease: Incorporating the New Consensus Summary Into Your Practice
This 30 minute CME program highlights the latest expert consensus on best practices for diagnosing Cushing’s disease and managing the comorbidities commonly observed in persons with this rare disorder.
Cushing’s disease is caused by an adrenocorticotropic hormone (ACTH)-secreting pituitary tumor. Optimal patient outcomes require an accurate diagnosis, proper selection of individualized treatment, and good management of the disease and its associated comorbidities.
The program feature... |
|
|
Updates in Medical Management of Cushing’s Syndrome: Incorporating the New Consensus Summary into Your Practice
This 30 minute CME program highlights the latest expert consensus on best practices for the treatment of persons with Cushing’s disease.
Cushing’s disease is caused by an adrenocorticotropic hormone (ACTH)-secreting pituitary tumor. Optimal patient outcomes require an accurate diagnosis, proper selection of individualized treatment, and good management of the disease and its associated comorbidities.
The program features two experts, Maria Fleseriu, MD, Professor of Medicine and Neur... |
|
|
Advances in Gene Therapy for Lysosomal Diseases
This CME/CE activity highlights the current trends in gene therapy for lysosomal storage diseases as well as some of the safety concerns with such therapy.
This activity provides continuing education credit for Physicians, Physician Assistants, Nurse Practitioners, Nurses, Genetic Counselors as well as a statement of participation for other participants. |
|
Optimizing Treatment Selection, Sequencing, and Tolerability in Small Cell Lung Cancer
This case-based podcast presented by i3 Health brings together two leading experts, Anne Chiang, MD, PhD, Associate Professor of Medicine, and Henry Park, MD, MPH, Chief of the Thoracic Radiotherapy Program, both at Yale School of Medicine, who will examine recent clinical advances and new opportunities in the management of SCLC and discuss key clinical questions engendered by recent advances in treatment and the need for individualized care. Start the activity now.
Statement of Need
An ... |
|
|
Novel Breast Cancer Therapies: Antibody-Drug Conjugates
STATEMENT OF NEED
Breast cancer is the most common cancer diagnosed in women, with an estimated 15% of cases being human epidermal growth factor receptor 2 (HER2)"positive and 12% being triple-negative (ACS, 2019). Antibody-drug conjugates have revolutionized the treatment of HER2-positive, triple-negative, and, most recently, HER2-low unresectable or metastatic breast cancer. These drugs combine a tumor antigen"targeted monoclonal antibody with a cytotoxic payload to permit the s... |
|
|
Novel Breast Cancer Therapies: Immune Checkpoint Inhibitors
STATEMENT OF NEED
Breast cancer is the most common cancer diagnosed in women, and it is
estimated that 12% of cases are classified as triple-negative for estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 (HER2) (ACS, 2019). Immune checkpoint inhibition in combination with chemotherapy is a new strategy in breast cancer, with the first immunotherapy approval for patients with advanced triple-negative disease occurring in 2019. Immune checkpoint inhibit... |
|
|
Novel Breast Cancer Therapies: CDK4/6 Inhibitors
STATEMENT OF NEED
Breast cancer is the most common cancer diagnosed in women, with 287,850 new cases and 43,250 deaths predicted to occur in 2022 (ACS, 2022). Making up 73% of cases, hormone receptor (HR)"positive/human epidermal growth factor receptor 2 (HER2)"negative disease is the most common subtype of breast cancer (ACS, 2019). Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors are a novel therapeutic option for patients with HR-positive, HER2-negative advanced breast cancer. T... |
|
|
Novel Breast Cancer Therapies: HER2 Tyrosine Kinase Inhibitors
STATEMENT OF NEED
Breast cancer is the most common cancer diagnosed in women, and it is estimated that 15% of cases are HER2-positive and may therefore benefit from human epidermal growth factor receptor 2 (HER2) inhibition (ACS, 2019). By blocking downstream oncogenic signaling in HER2-positive breast cancer cells, HER2 tyrosine kinase inhibitors improve outcomes for patients with HER2-positive breast cancer. These agents have advantages over monoclonal antibody HER2 inhibitors because the... |
|
|
Novel Breast Cancer Therapies: Monoclonal Antibodies
STATEMENT OF NEED
Breast cancer is the most common cancer diagnosed in women, and it is estimated that 15% of cases are human epidermal growth factor receptor 2 (HER2)"positive and may therefore benefit from HER2 inhibition (ACS, 2019). Monoclonal antibodies target HER2 function by preventing the formation or blocking the signaling of the oncogene HER2. The resulting loss of signaling downregulates oncogenic signaling in the cancer cell, resulting in improved clinical outcomes for pati... |
|
|
Novel Breast Cancer Therapies: PARP Inhibitors
STATEMENT OF NEED
Breast cancer is the most commonly diagnosed cancer in women. A BRCA1 or BRCA2 mutation is found in approximately 5% of patients with breast cancer and is detected in 30% of patients who have a family history of breast or ovarian cancer (ACS, 2019). In patients with human epidermal growth factor receptor 2 (HER2)"negative breast cancer with deleterious or suspected deleterious germline BRCA mutations, inhibition of poly"(ADP-ribose) polymerase (PARP) is highly ef... |
|
|
Novel Breast Cancer Therapies: PI3K Inhibitors
STATEMENT OF NEED
Breast cancer is the most diagnosed cancer in women, with hormone receptor (HR)"positive/human epidermal growth factor receptor 2 (HER2)"negative breast cancer being the most common subtype, making up 73% of cases (ACS, 2019). In breast cancer, phosphatidylinositol-3-kinase (PI3K) overactivation is often associated with an activating mutation in the catalytic alpha subunit of PI3K (PIK3CA). These activating mutations occur in more than one third of breast cancers... |
|
|
Growth Hormone Deficiency Research Highlights
This 15-minute CME program highlights the latest clinical research about Growth Hormone Deficiency (GHD).
GHD is a rare endocrine disorder characterized by insufficient levels of growth hormone being secreted from the anterior pituitary gland. A hallmark of prolonged GHD is growth retardation or deceleration, as well as short stature. Additionally, growth hormone deficiency is associated with metabolic abnormalities, impaired cardiovascular function, fatigue, delayed or incomplete puberty, ... |
|
|
PAH Research Highlights from CHEST
PAH is a rare, progressive disorder characterized by high blood pressure in the pulmonary arteries. Symptoms of PAH include shortness of breath (dyspnea) especially during exercise, chest pain, and fainting episodes. The progressive nature of this disease means that an individual may experience only mild symptoms at first, but will eventually require treatment and medical care to maintain a reasonable quality of life. There are numerous treatment options and options in development for persons ... |
|
|
Cushing’s Disease / Cushing’s Syndrome Research Highlights
This 30-minute CME program highlights the latest clinical research about Cushing’s disease and Cushing’s syndrome.
Cushing’s disease is caused by an adrenocorticotropic hormone (ACTH)-secreting pituitary tumor that leads to excessive levels of cortisol. Cushing’s syndrome is also characterized by excessive levels of cortisol but can be due to a variety of reasons.
This CME program, hosted by Richard Auchus, MD, PhD Professor at the University of Michigan, provides an overview of ... |
|
|
Evolving Treatment Concepts and New Data in Advanced Prostate Cancer
STATEMENT OF NEED
Prostate cancer is the most common tumor type affecting men in the United States. It is estimated that 268,490 new cases were diagnosed and that 34,500 people died of prostate cancer in 2022 (Siegel et al, 2022). Prostate cancer alone accounts for 27% of all cancer diagnoses in men (ACS, 2022). To optimize outcomes for patients with prostate cancer, it is critical for health care providers to be familiar with the most recent evidence on therapy selection, biomarker testing... |
|
|
Cracking the Code for Improved Patient Outcomes in Advanced Renal Cell Carcinoma
STATEMENT OF NEED
Renal cell carcinoma (RCC) comprises 2.4% of malignancies in adults worldwide (Makino et al, 2022). It is estimated that 79,000 new cases of kidney cancer were diagnosed in the US in 2022 (Siegel et al, 2022). RCC is characterized by a lack of early warning signs, diverse clinical manifestations, and resistance to radiation and chemotherapy. Several new therapies have been approved for RCC in recent years; therefore, it is important for the cancer care team to update their... |
|
|
Oncology Data Advisor™: Aligning Treatment Goals and Value-Based Care in Newly Diagnosed Multiple Myeloma
STATEMENT OF NEED
Multiple myeloma is a clonal plasma cell malignancy characterized by several cytogenetic alterations. Treatment planning for individual patients is complicated by factors such as age, frailty, comorbidities, eligibility for autologous stem cell transplantation, and risk stratification (Kumar et al, 2022). Clinicians need to continually update their working knowledge of emerging data and consensus recommendations that can rationally inform clinical decision making. In Modul... |
|
|
Virtual Tumor Board: Building Comprehensive Care Plans in Esophagogastric Cancers
STATEMENT OF NEED
Esophagogastric cancers include tumors of the esophagus, esophageal junction, and stomach. Esophageal cancers are the twentieth most commonly diagnosed cancer in the United States, but the eleventh leading cause of cancer death, with an estimated 21,560 cases diagnosed annually and 16,120 deaths estimated in 2023 (NCCN, 2023; Siegel et al, 2023). Given the poor prognosis of esophagogastric cancers and the complexity of personalized care planning, interdisciplinary teamwork... |
|
|
Fabry Disease Research Highlights
This 30-minute CME-accredited program highlights the latest clinical research about Fabry disease, a rare X-linked lysosomal disorder that results in the cellular buildup of globotriaosylceramide. Characteristic features of Fabry disease include acroparesthesias, angiokeratomas, hypohidrosis, corneal opacity, gastrointestinal problems, tinnitus, and hearing loss. Fabry disease also involves potentially life-threatening complications such as progressive kidney damage, heart attack, and stroke.
... |
|
|
Leveraging BCMA-Directed Therapies for Improved Patient Outcomes in Relapsed/Refractory Multiple Myeloma
STATEMENT OF NEED
Multiple myeloma is a disease that remains incurable for most patients, many of whom become refractory to the majority of available treatments (Kumar et al, 2022). It is estimated that 35,730 new cases of multiple myeloma are diagnosed in the United States annually, and 12,590 people die of the disease (Siegel et al, 2023). Agents targeting B-cell maturation antigen (BCMA), including antibody-drug conjugates (ADCs), chimeric antigen receptor (CAR) T-cell therapies, and bis... |
|
|
Warm Autoimmune Hemolytic Anemia (wAIHA)
Warm autoimmune hemolytic anemia (wAIHA) is the most common type (60-70%) of autoimmune hemolytic anemia (AIHA). In most cases, wAIHA is due an immunoglobulin G (IgG) autoantibody that binds to red blood cells (RBC), leading to hemolysis.
Current recommendations for managing people with wAIHA are largely based on case series and retrospective studies involving off-label medications. Also, while there are currently no medications specifically approved to treat wAIHA, data are emerging on new... |
|
|
Hitting the Target in HER2-Positive Metastatic Colorectal Cancer
STATEMENT OF NEED
An estimated 153,020 new cases of colorectal cancer (CRC) are diagnosed annually, and 52,550 people die of the disease (Siegel et al, 2023). Approximately 22% of patients present with metastatic disease, which is associated with a dismal 5-year survival rate of 15% (SEER, 2022). Targeting biomarkers is a key strategy for expanding therapeutic options and improving outcomes in metastatic CRC. Human epidermal growth factor receptor 2 (HER2) amplification status and treatment... |
|
|
Building and Maintaining a Multidisciplinary Team for Lysosomal Disorders
This CME/CE activity with Drs. Ozlem Goker-Aplan and Walla Al-Hertani describes the importance of a multidisciplinary team approach to managing lysosomal diseases, as well as some of the challenges involved in creating and maintaining that team.
At the end of this activity, participants should be able to:
- Describe the need for a team approach to care
- Describe best practices to build a multidisciplinary team for a new patient
- Describe best practices to maintain a multidisciplinary... |
|
|
Expert Guidance on Current Standards and New Directions in Newly Diagnosed Multiple Myeloma
STATEMENT OF NEED
An estimated 35,730 new cases of multiple myeloma are diagnosed in the United States annually, and 12,590 people die of the disease (Siegel et al, 2023). Characterized by clonal proliferation of malignant plasma cells in the bone marrow, multiple myeloma is associated with anemia, renal insufficiency, bone destruction, and hypercalcemia, all of which significantly impact patients’ quality of life. The development of novel therapies and combinations in recent years, inclu... |
|
|
Myasthenia Gravis Research Highlights: AAN 2023
This 30-minute CME program highlights the latest clinical research about myasthenia gravis, a rare, autoimmune disease that targets the neuromuscular junction.
Treatment of myasthenia gravis is highly individualized and depends greatly on the myasthenia gravis subtype of each patient as well as each patient’s comorbidities. There are currently four drugs approved by the FDA, eculizumab, efgartigimod, ravulizumab, and rozanolixizumab. There are also treatments in development. Clinical tria... |
|
|
Leveraging the Growing Arsenal of Adjuvant Therapies for Early-Stage NSCLC
In this activity, Dr. Helena A. Yu, Associate Attending Physician at Memorial Sloan Kettering Cancer Center, will provide insights into strategies for leveraging the growing arsenal of adjuvant therapies for early-stage non"small cell lung cancer (NSCLC), including treatment selection and adverse event management. Start the activity now!
STATEMENT OF NEED
Lung cancer is the second most commonly diagnosed cancer and the leading cause of death for men and women worldwide. In the Unite... |
|
|
Pathology and Oncology Expert Perspectives in the Management of Triple-Negative Breast Cancer: Case Explorations and Answers to FAQs
STATEMENT OF NEED
Triple-negative breast cancer (TNBC) is an aggressive disease that accounts for approximately 10% to 15% of breast cancer diagnoses and is characterized by the absence of estrogen receptors, progesterone receptors, and human epidermal growth factor receptor 2 (HER2). TNBC is more common in Black women and in women under the age of 40 (ACS, 2023). Compared with other subtypes of invasive breast cancer, TNBC has high rates of metastasis and a poor prognosis. Due to the lack ... |
|
|
Virtual Tumor Board: Multidisciplinary Management of Advanced Soft Tissue Sarcoma
STATEMENT OF NEED
Sarcomas, which represent 1% to 2% of adult cancers, are a rare, heterogeneous group of neoplasms originating in the connective tissue. Soft tissue sarcomas, which begin in the muscle, tendons, fat, lymph, blood vessels, and nerves, encompass more than 80 histological subtypes. Approximately 25% of patients develop metastatic disease after curative-intent surgery, and for these patients, treatment options are limited and prognosis is very poor. In recent decades, the ident... |
|
|
Putting the Freeze on Cold Agglutinin Disease
STATEMENT OF NEED
Cold agglutinin disease (CAD) is a rare subtype of autoimmune hemolytic anemia (AIHA) in which antibodies cause hemolysis at cold temperatures, generally between 37º to 39º Fahrenheit. Approximately 1 in a million people are affected by CAD annually, with onset usually occurring between the ages of 40 and 80 years. Individuals commonly experience fatigue, dizziness, palpitations, and shortness of breath caused by the anemia; jaundice caused by degradation of hemoglobin i... |
|
|
Exploring New Treatment Advances for Acid Sphingomyelinase Deficiency in Adults
STATEMENT OF NEED
Acid sphingomyelinase deficiency (ASMD) is a rare, hereditary lysosomal storage disease with multisystemic manifestations, including splenomegaly, hepatomegaly, interstitial lung disease, dyslipidemia, bone marrow and lymph node involvement, and sometimes neurological and peripheral nerve involvement. While the most severe form of ASMD, infantile neurovisceral ASMD, results in death in early childhood, chronic forms of ASMD have more prolonged survival but are associated w... |
|
|
Current Standards and New Directions in the Treatment of Acquired Thrombotic Thrombocytopenic Purpura
STATEMENT OF NEED
Acquired thrombotic thrombocytopenic purpura (aTTP) is a rare, life-threatening thrombotic microangiopathy with a rapid onset and progression and a mortality rate of 10% to 20% with prompt treatment. Onset of aTTP is characterized by severe thrombocytopenia, microangiopathic hemolytic anemia, and a constellation of associated symptoms including hemorrhage, neurologic and renal manifestations, cardiac abnormalities, and mesenteric ischemia (Joly et al, 2017). Survivors of f... |
|
|
Recurrent and Metastatic HNSCC: New Insights and Real-World Evidence for Improved Patient Outcomes
STATEMENT OF NEED
Head and neck cancers represent a heterogeneous group of tumors that originate in the lip/oral cavity, hypopharynx, oropharynx, nasopharynx, and larynx. An estimated 66,470 new cases are diagnosed in the United States annually, and 15,050 people die of the disease (Siegel et al, 2022). Approximately 90% of cases are classified as head and neck squamous cell carcinoma (HNSCC). Treatment of HNSCC is complicated by numerous factors, including differing therapeutic strategies ... |
|
|
Fetal and Women's Imaging 2023- Advanced OB-GYN Ultrasound
World Class CME is again proud to host the annual Fetal and Women's Imaging conference in Seattle, Washington. We welcome everyone to The Westin Seattle for yet another excellent three day course in 2023.
This course is designed for physicians and sonographers in the fields of gynecologic and obstetric imaging, as well as residents in obstetrics and gynecology, or radiology, and fellows in maternal-fetal medicine. This course may also be valuable to family physicians practicing obstetr... |
|
|
A Breath of Fresh Air: New Treatment Strategies for Chronic Rhinosinusitis with Nasal Polyps
Agenda
Welcome and Introduction
Identifying the Source of the Problem
Finding an Effective Treatment
Q & A Session and Activity Roundup
Target Audience
The intended audience for this educational initiative includes primary care physicians, allergists and other clinicians who manage patients with chronic rhinosinusitis with nasal polyps.
Program Overview
This activity will review the major causes of nasal polyps and how to diagnose CRSwNP, the pathophysiology of CRSwNP, the safety... |
|
|
Treatment-Related Adverse Events in Advanced Urothelial Carcinoma
Target Audience
This activity is designed to meet the educational needs of physicians and other healthcare professionals involved in the care of urothelial carcinoma.
Program Overview
This interactive case-based activity requires clinicians to make real-world decisions as they optimize therapeutic strategies for patients with advanced urothelial carcinoma.
Throughout the activity, practitioners will have the opportunity to immediately implement expert guidance and evaluate performance ... |
|
|
Treatment-Related Adverse Events in Advanced Urothelial Carcinoma
Target Audience
This activity is designed to meet the educational needs of physicians and other healthcare professionals involved in the care of urothelial carcinoma.
Program Overview
This interactive case-based activity requires clinicians to make real-world decisions as they optimize therapeutic strategies for patients with advanced urothelial carcinoma.
Throughout the activity, practitioners will have the opportunity to immediately implement expert guidance and evaluate performance ... |
|
|
What’s My (Next) Line? Treating Relapsed/Refractory Multiple Myeloma When Three Prior Treatment Lines Fail
Although outcomes for patients with multiple myeloma (MM) have improved with targeted agents and combination therapies, most MM patients inevitably relapse. Furthermore, the duration and quality of response to treatment deteriorates following each subsequent line of therapy, and the risk of another relapse rises. The emergence of B-cell maturation antigen (BCMA)-targeting antibody-drug conjugates, bispecific antibodies, CAR T-cell therapy, and novel small-molecule agents has offered innovative... |
|
|
Hidradenitis Suppurativa (HS): Optimizing the Management Approach with Treatments
Target Audience
This educational activity is directed toward dermatologists, nurse practitioners, physician assistants, nurses, and other health care professionals who are involved in the treatment and management of HS. Primary care providers and women’s health professionals who may be involved in first-line diagnosis of HS are also invited to participate.
Activity Overview
This online educational activity is designed to provide an expert disease overview of hidradenitis suppurativa (HS... |
|
|
Advances in™ Hidradenitis Suppurativa (HS): Optimizing the Management Approach with Available and Emerging Treatments
Target Audience
This educational activity is directed toward dermatologists, nurse practitioners, physician assistants, nurses, and other health care professionals who are involved in the treatment and management of HS. Primary care providers and women’s health professionals who may be involved in first-line diagnosis of HS are also invited to participate.
Activity Overview
This online educational activity is designed to provide an expert disease overview of hidradenitis suppurativa (HS... |
|
|
7th Annual National Hospitalist Conference
The 7th Annual National Hospitalist Conference on October 3-6, 2023 at the Sheraton Denver Downtown Hotel is designed to provide attendees with the information and skills to improve the care of hospitalized patients. This conference has been accredited for up to 16 CME credits.
The conference's focus is on the practical management of problems commonly encountered in hospital medicine. An emphasis will be placed on recent advances, up-to-date practices, and guidelines for inpatient care... |
|
|
Multidisciplinary Pelvic Health Update: From Population Health to Personalized Care
Last year we ‘focused on function’ with an emphasis on metrics for measuring patient symptoms. This year our focus is on how to individualize treatments based on guidelines and population health, with an emphasis on algorithms of care that highlight the roles of the multidisciplinary teams in medical and surgical management. It will include three "supersessions" on defecatory disorder, urologic conditions, and pelvic pain management. Case and panel discussions between plenary spe... |
|
|
Case Studies in Syphilis and Mpox: A STEP-HIV Initiative
Members of the HIV care team are confronting two growing challenges"one old and one new.
Syphilis rates reached a historic low in 2000/2001 but have since increased annually and have reached a disturbing trend nationally affecting all communities. People living with HIV (PLWH) are particularly vulnerable to this infection and its complications.
Cases of human monkeypox virus (which is endemic to parts of western and central Africa), have risen steadily in the U.S. over the past few ... |
|
|
Are You Up to Date on Your Flu Season Response? Flexing Your Clinical Management Muscles
Influenza is a highly contagious seasonal viral infection that affects all age cohorts. While vaccination is still the best way to prevent influenza-associated illness, under-vaccination and other factors contribute to significant morbidity and mortality during influenza season. Timely use of influenza antiviral therapies can play a critical role in reducing disease severity, duration, and transmission, and therapy indications have recently expanded. Are You Up to Date on Your Flu Season Respo... |
|
|
Splendors of Southern Europe Cruise: Exploring Medicine, Dentistry & the Mediterranean Healthcare Model
Exploring Medicine, Dentistry & the Mediterranean Healthcare Model
CME/CE Lecture Seminars for Medical, Dental, Nursing, and Allied Healthcare Professionals
This Seminar is planned for 12 Continuing Education Credit Hours.
CME/CE Professional Seminar Fee: $695
Seminar Attendance Fee: $450
CME/CE credits, Certificates of Completion and possible tax deductible guidelines will be provided for registered Professional Seminar attendees Certificates of Attendance will be provi... |
|
|
Community Practice Connections™: Comprehensive Key Advances in Biosimilars for Retinal Diseases " Reviewing the Evidence, Addressing Patient Perspectives, and Practice Utilization for the Retina Speci
Target Audience
This educational activity is directed toward retinal and general ophthalmologists and other health care professionals involved in the treatment of patients with retinal diseases, such as optometrists, advanced practitioners, and nurses.
Program Overview
Regular intravitreal injections of vascular endothelial growth factor (VEGF) inhibitors are a standard of care for retinal diseases such as neovascular age-related macular degeneration and diabetic retinopathy. However, fre... |
|
|
Shaping the Management of Multiple Sclerosis " The Potential for BTK Inhibitors in Clinical Practice
Activity Overview
Advances in the understanding of immune mechanisms that contribute to the pathophysiology of multiple sclerosis (MS) have led to the development of many disease-modifying therapies that target effector T cells, regulatory cells, B cells, and cell trafficking into the nervous system. Among these emerging pathways is use of Bruton tyrosine kinase (BTK) inhibitors, which block the actions of B cells and may affect other cell types that can facilitate inflammation. This bridging... |
|
|
Community Practice Connections™: Comprehensive Key Advances in Biosimilars for Retinal Diseases " Reviewing the Evidence, Addressing Patient Perspectives, and Practice Utilization for the Retina Speci
Target Audience
This educational activity is directed toward retinal and general ophthalmologists and other health care professionals involved in the treatment of patients with retinal diseases, such as optometrists, advanced practitioners, and nurses.
Program Overview
Regular intravitreal injections of vascular endothelial growth factor (VEGF) inhibitors are a standard of care for retinal diseases such as neovascular age-related macular degeneration and diabetic retinopathy. However, fre... |
|
|
Clinical Approaches to Obesity Management
This goal of this remote webinar is to educate attendees about the therapeutic use and safety considerations with available treatment options for obesity in persons with and without diabetes. This program is accredited for a total of 2.0 contact hours (0.2 CEU) of continuing education credit. Learning objectives are provided below:
Obesity in patients with diabetes:
-Review clinical practice guidelines for the management of type 2 diabetes
-Compare pharmacologic treatment options that pro... |
|
|
Neoadjuvant and Adjuvant Treatment in Early-Stage NSCLC: Options Are Expanding " An In the Clinic Activity
TARGET AUDIENCE:
This educational activity has been designed to meet the needs of medical, surgical, and radiation oncologists and other clinicians who treat and manage patients with lung cancer.
PROGRAM OVERVIEW:
The introduction of immune checkpoint inhibitors (ICI) into the treatment of non-small cell lung cancer (NSCLC) has changed the treatment paradigm and become the standard of care in advanced stage lung cancer. Recent and ongoing efforts to replicate the remarkable success of imm... |
|
|
Introduction to Abdominal and Primary Care Ultrasound
Introduction to Abdominal & Primary Care Ultrasound Live Training Course is taught by leading abdominal and primary care ultrasound experts and covers liver, Gallbladder/biliary tree, renal/bladder, pancreas, spleen, abdominal aorta, GI tract, trauma, thyroid, scrotal, and soft-tissue applications. The abdominal and primary care ultrasound courses include lectures, interactive case presentations, and extensive hands-on skills training featuring the industry lowest 3:1 participant to facult... |
|